EUVIMEDEUVIMED entdecken
Crossref

Conjugatability and Physicochemical Stability of an Infliximab–vcMMAE Antibody–Drug Conjugate

Yutaka Matsuda iD, Monica Leung, Zhala Tawfiq, Veronica Robles, Yuichi Nakahara, Brian A Mendelsohn iD

Biomedical Chromatography · 2026-12 · 40 (12)

DOI: 10.1002/bmc.70648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 28.10.2026. Verfasst von Yutaka Matsuda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ajinomoto Bio-Pharma Services, San Diego, California, USA. Hauptthemen laut MEDLINE: Infliximab, Immunoconjugates. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transmembrane tumor necrosis factor (tmTNF) can support internalization of anti‐TNF antibodies, providing a mechanistic rationale for exploring anti‐TNF antibody‐drug conjugate formats. We evaluated infliximab as a scaffold for conventional interchain‐cysteine conjugation using an MC‐valine‐citrulline‐PABC‐MMAE linker‐payload (vcMMAE). Increasing tris(2‐carboxyethyl)phosphine (TCEP) from 2.2 to 2.6 equivalents increased the average drug‐to‐antibody ratio (DAR) from 3.12 to 3.65 by reduced RP‐HPLC and from 3.5 to 4.1 by hydrophobic interaction chromatography (HIC). SEC‐detectable high‐molecular‐weight (HMW) species remained approximately 1% across the conjugates, comparable to unconjugated infliximab (1.1%). A selected preparation with an average DAR of approximately 4 showed no substantial change in its SEC profile after five freeze–thaw cycles or incubation at 37°C for 2 weeks. These results demonstrate that infliximab is amenable to conventional interchain‐cysteine conjugation to approximately DAR = 4 without an evident increase in SEC‐detectable HMW species and provide an initial chromatographic assessment of its post‐conjugation physicochemical stability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabImmunoconjugatesDrug StabilityChromatography, High Pressure LiquidHydrophobic and Hydrophilic InteractionsCysteineChromatography, Gel

Stichwörter der Autor:innen

antibody‐drug conjugatecysteine conjugationdrug‐to‐antibody ratioinfliximabphysicochemical stability

Substanzen

InfliximabImmunoconjugatesCysteine

Autor:innen und Institutionen

  • Ajinomoto Bio-Pharma Services, San Diego, California, USA.
  • Ajinomoto Co. Inc, Kawasaki, Kanagawa, Japan.

ORCID-Profile: Yutaka Matsuda, Brian A Mendelsohn

Zitieren

APA

Matsuda, Y., Leung, M., Tawfiq, Z., Robles, V., Nakahara, Y., & Mendelsohn, B. A. (2026). Conjugatability and Physicochemical Stability of an Infliximab–vcMMAE Antibody–Drug Conjugate. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70648

Vancouver

Matsuda Y, Leung M, Tawfiq Z, Robles V, Nakahara Y, Mendelsohn BA. Conjugatability and Physicochemical Stability of an Infliximab–vcMMAE Antibody–Drug Conjugate. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70648

BibTeX
@article{Matsuda2026,
  author = {Matsuda, Yutaka and Leung, Monica and Tawfiq, Zhala and Robles, Veronica and Nakahara, Yuichi and Mendelsohn, Brian A},
  title = {Conjugatability and Physicochemical Stability of an Infliximab–vcMMAE Antibody–Drug Conjugate},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {12},
  doi = {10.1002/bmc.70648}
}
Kostenlos starten →